ABBV · AbbVie Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 31, 2026TL;DR. AbbVie delivered Q2 adjusted EPS of $3.65, $0.06 above guidance, with revenue up 10.2%, and raised full-year revenue guidance by $300M while cutting adjusted EPS guidance by $0.04 at the midpoint to incorporate $0.14 of Apogee acquisition dilution that more than offsets $0.10 of underlying overperformance.
- + Q2 adjusted EPS beat guidance midpoint by $0.06 on 10.2% revenue growth
- + Raised Skyrizi full-year revenue guidance by $100M to $21.7B
- + Raised neuroscience full-year revenue guidance by $100M to $12.7B
- + Q2 GAAP diluted EPS rose 290.4% to $2.03 and adjusted diluted EPS rose 22.9% to $3.65
- − Lowered full-year adjusted EPS guidance midpoint by $0.04 to $13.87-$14.07 due to Apogee dilution
- − Apogee acquisition expected to add $0.14 of dilution and increase net interest expense by $200M
- − Humira sales declined 36.1% operationally to $756M from biosimilar competition
- − Imbruvica sales declined 29.4% on IRA pricing and competitive pressure
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABBV
this stock
AbbVie Inc.
|
$466.80B | +15.2% | +8.6% | 74.6 | 1.1% |
|
LLY
ELI LILLY & Co
|
$1.11T | +10.2% | +44.7% | 39.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$653.61B | +29.3% | +6.0% | 31.5 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$367.07B | +41.8% | +1.3% | 119.0 | 1.4% |
|
NVS
Novartis AG
|
$276.48B | +5.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABBV | -0.7% | +2.7% | +24.4% | +2.7% | +15.2% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +0.5% | +3.1% | +11.4% | +3.1% | +3.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.